**ABSTRACT**

**Background**

Despite many critical voices regarding its efficacy and safety, digoxin may still have a role in the management of heart failure. The objective of this study was to evaluate the efficacy and safety of a short course digoxin therapy started in the emergency department based on clinical outcome after 30 days post hospital discharge.

**Methods**

From Great Tunisian registry, acute decompensated heart failure (ADHF) patients from January 2016 to January 2018 were identified. Patients with incomplete data were excluded. Digoxin treated and non-treated patients were compared in a matched control study with respect to primary outcomes of all-cause mortality and HF readmission. Secondary outcomes included changes of cardiac output (CO) and left ventricular ejection fraction (LVEF) after 72 hours of hospital admission.

**Results**

The study population comprised 104 digoxin treated and 229 matched non-treated with a median age of 67.4±12.8. After 72 hours of ED admission, there was a larger increase of CO (17.8 % vs 14%; p=0.015) and LVEF (14.4% vs 3.5%; p=0.003) in digoxin group compared to control group. At 30-day post-hospital discharge 34 (10.2%) patients died and 72 (21.6%) patients were readmitted. Use of digoxin was associated with decreased risk of death and hospital readmission [odds ratio, 0.79 (95% CI, 0.71-0.89)].

**Conclusion**

In ADHF patients, treatment with digoxin was associated with a significant decrease risk of 30-day mortality and hospital readmission with an improvement of cardiac output and left ventricular ejection fraction.

**Key words:** Acute heart failure; digoxin; mortality; rehospitalization; emergency department.

**INTRODUCTION**

Heart failure (HF) is a major worldwide health problem and one of the most important causes of hospital admissions [1,2]. These hospitalizations are responsible for an important economic burden and are associated with high mortality rates, up to 20% following hospital discharge [3,4]. Acute decompensated HF (ADHF) management is difficult given the heterogeneity of the patient population, incomplete understanding of its pathophysiology and lack of evidence-based guidelines. Although the majority of patients with ADHF appear to respond well to initial therapies consisting of loop diuretics and vasoactive agents, these first line treatments failed to decrease post-discharge mortality and readmission rate [5,6]. Investigations of novel therapies such as serelaxin did not show a significant clinical benefit. In a recent multicenter, double-blind, placebo-controlled trial including patients who were hospitalized for acute heart failure, it was shown that the risks of death at 180 days were...
not lower in patients who had received intravenous serelaxin for 48 hours than in patients who had received placebo [7]. Numerous other clinical trials have been published on ADHF treatment and their results were disappointing in term of efficacy and/or safety [8-11]. Digoxin is one of the oldest compounds in cardiovascular medicine but its beneficial effect is very controversial [12]. Yet, digoxin has many potential beneficial properties for heart failure as it is the only oral inotrope available that did not alter blood pressure neither renal function. Despite its useful hemodynamic, neurohormonal, and electrophysiological effects in patients with chronic congestive HF, concerns about digoxin safety were constantly highlighted [13]. Consequently, the use of digoxin has decreased considerably, in the last 15 years [12]. Digoxin under prescribing is problematic for several reasons. First, it underestimated the substantial beneficial effect of digoxin on the reduction of hospital admissions in HF patients. Second, for its low cost, the favorable cost-effectiveness ratio of digoxin is highly desirable in low-income countries. Moreover, the question whether a short course of digoxin is useful in ADHF was not previously investigated in the era of new heart failure therapies including β-blockers, angiotensin converting enzyme inhibitors and angiotensin-receptor blockers [12]. The objective of this study is to assess the efficacy and safety of a short course digoxin in patients admitted to the ED with ADHF (Figure 1 and Figure 2).

PATIENTS AND METHODS

Data Source

We conducted a retrospective matched case-control study to assess the association between digoxin treatment and 30-day outcome in patients with ADHF. The ADHF patients were identified from the Great Tunisian database between January 2016 and January 2018. The patients included are residents of a community of 500,000 inhabitants in the east of Tunisia, served by 2 university hospitals (Fattouma Bourguiba Monastir, and Sahloul Sousse). ADHF was defined as an acute onset of symptoms within 48 hours preceding presentation, dyspnea at rest or with minimal exertion, evidence of pulmonary congestion at chest radiograph or lung ultrasound, NT-proBNP ≥1400 pg/ml. This electronic medical recording system provided detail of each patient admitted to emergency department (ED) for acute undifferentiated non traumatic dyspnea.

Study Population

Patients were included if the following data are available: demographic characteristics, comorbidities, current drug use, baseline NYHA functional class, physical exam findings, standard laboratory tests, brain natriuretic peptide levels at ED admission; echocardiographic results, biomarkers; measured cardiac output at ED admission and at hospital discharge, digoxin daily dose, 30-day follow-up information including ED readmission and survival status. A patient who received at least 0.25 mg of oral digoxin (1 tablet) for three days during hospital stay was defined as case; those who did not receive digoxin treatment were selected as control. The protocol used in this study was approved by the ethics committee of our institution, and all subjects gave their written informed consent to be included in the data base. All the listed criteria have to be fulfilled for patient’s inclusion.

Figure 1: Patients inclusion/exclusion Flowchart

1727 patients assessed for eligibility

402 excluded
- 956 with non-cardiac cause of dyspnea
- 211 with incomplete data

333 Randomly assigned

104 assigned to digoxin group
229 assigned to the control group

Figure 2: Cardiac output (CO) and left ventricular ejection fraction (LVEF) change from baseline at 72 hours in digoxin (DIG) and control groups.

£p=0.015 vs baseline, * p=0.003 vs control group.
Outcomes were shown in Table 1. Demographic characteristics were higher (0.5mg) dose. Baseline characteristics of both groups days. Only few patients received a lower (0.125 mg) or a dose (0.25 mg, one tablet) each day during at least three days. Almost all of our patients received the same digoxin treatment. Data are reported as means ± standard deviations, unless otherwise noted, and a p-value less than 0.05 via two-sided testing was considered statistically significant. Data were analyzed using the statistical software package SPSS version 18.

RESULTS

The initial study population comprised 1727 participants who were registered in the database. From this initial population, we excluded 956 with non-cardiac cause of dyspnea, and 211 with incomplete data. From the remaining patients, 104 were included in the digoxin group and 229 in the control group. Digoxin was orally administered once a day and almost all of our patients received the same dose (0.25 mg, one tablet) each day during at least three days. Only few patients received a lower (0.125 mg) or a higher (0.5mg) dose. Baseline characteristics of both groups are shown in Table 1. Demographic characteristics were comparable among both study’s groups. There were no relevant differences in age, sex, or NYHA classification. The NYHA class collected was related to base line medical status (within three months before the ongoing exacerbation). Cardiovascular medical history was comparable for both groups. There were no significant differences between cases and controls regarding underlying other comorbidities. Fifty-two percent of the patients had ischaemic cardiomyopathy as the primary aetiology of their heart failure (47-57%) (Table1). Principal baseline medication consisted of diuretics, angiotensin converting enzyme-inhibitors, beta-blockers, and nitrates. Mean vital signs values at baseline were comparable among the 2 groups with respect to heart rate, respiratory rate, and blood pressure. NT-proBNP levels ranged from 1412 to 8615 pg/ml between; 61% in digoxin group and 59% in control group had reduced LVEF (<45%) (p=0.77). After 72 hours of ED admission, there was a larger increase of CO (17.8% vs 14%; p=0.015) and LVEF (14.4% vs 3.5%; p=0.003) in digoxin group compared to control group (Figure 1); NTpro BNP levels decreased and in digoxin group (2%) and in control group (1.2%) but the difference was not significant (p=0.06). Digoxin treatment was associated with a reduced length of hospital stay (10.1±7.2 days versus 6.6±3.5%; p=0.003) in digoxin group compared to control group (2%) and in control group (1.2%) but the difference was not significant (p=0.06). Digoxin treatment was associated with a reduced length of hospital stay (10.1±7.2 days versus 6.6±3.5%; p<0.01). At 30-day follow-up, digoxin group showed a significantly lower all-cause (p=0.04) and heart failure (p=0.02) hospital readmission rate compared to control group, and lower mortality (11.8% versus 6.7%; p=0.03) (Table 2). Digoxin treatment was found to significantly decrease the odds for the combined events of mortality and hospital readmission [odds ratio, 0.79 (95% CI, 0.71-0.89)]. No major side effects were observed in relation to digoxin therapy.

DISCUSSION

Our results demonstrated that digoxin is associated with a lower risk of 30-day hospital readmission among ED patients with decompensated HF. Compared with control group, LVEF and cardiac output increased and length of hospital stay decreased significantly in digoxin-treated group. Most available studies analyzed long-term effect of digoxin in patients with chronic heart failure, but data on the effect of short course digoxin on early clinical outcome and physiological related parameters in patients with acute heart failure are scarce. The concordance between physiological and clinical outcomes was in favor of the validity of our results. Digoxin is one of the oldest drugs used in cardiology practice, and few decades ago, it was prescribed in more than 60% of heart failure patients in the United States [14]. Digoxin is the only inotropic drug known to increase cardiac output and to reduce pulmonary capillary pressure without increasing heart rate or lowering blood pressure in contrast to other oral inotropes. However, despite the evidence of
Table 1: Baseline characteristics of both study group

|                      | Control n=229 | Digoxin n=104 | P  |
|----------------------|---------------|---------------|----|
| Sex (H/F)            | 121/108       | 53/51         | 0.25 |
| Age year mean (SD)   | 67.3 ±14.2    | 67.7 ± 12.3   | 0.86 |
| Comorbidity n (%)    |               |               |    |
| Hypertension         | 128(55.8)     | 53(50.9)      | 0.66 |
| Diabetes             | 73 (31.8)     | 39(37.5)      | 0.26 |
| Coronary artery disease | 29(12.7)  | 12(11.5)      | 0.34 |
| Chronic heart failure | 77(33.6)   | 38(36.5)      | 0.25 |
| Chronic obstructive pulmonary disease | 52(22.7) | 27(25.9)      | 0.11 |
| Dyslipidemia         | 18(7.9)       | 10(9.6)       | 0.17 |
| Smoking              | 131(57.2)     | 50(48)        | 0.52 |
| NYHA class* n (%)    |               |               | 0.12 |
| I                    | 11(4.8)       | 4(3.8)        |    |
| II                   | 52(22.7)      | 25(24)        |    |
| III                  | 95(41.5)      | 49(47.1)      |    |
| VI                   | 71(31)        | 26(24.1)      |    |
| Systolic blood pressure (mmHg) | 33.3 ±3.9 | 29 ±6.14      | 0.65 |
| Diastolic blood pressure (mmHg) | 143.3 ±30.9 | 144.7 ±35.8 | 0.8 |
| Heart rate (b/min)   | 81 ±22.19     | 72.8 ±26.1    | 0.07 |
| Respiratory rate (c/min) | 100.6±25.4 | 100.1±21.1    | 0.89 |
| Pulse oxygen saturation (%) | 24.8 ±5.5 | 24.5 ±5.4 | 0.74 |
| LVEF (%)             | 40±6.2        | 40.1±3.5      | 0.615 |
| Glycemia (mmol/L)    | 17.1±3.2      | 11.2±7        | 0.59 |
| Serum Creatinin (µmol/L) | 88±22 | 95±18 | 0.13 |
| Hemoglobin (mmol/L)  | 12.6±2.4      | 13.6±2        | 0.32 |
| Serum sodium (mmol/L) | 134±27        | 135±5         | 0.84 |
| Serum potassium (mmol/L) | 15.2±6.2    | 23.6±9.1      | 0.37 |
| NT pro-BNP (pg/ml) median (IQR) | 3071(1860-7085) | 3580(1412-8615) | 0.32 |

IQR: interquartile range

*NYHA related to base line medical status (within three months before the ongoing exacerbation)
its beneficial effects on hemodynamic, neuro-hormonal and electrophysiological parameters, a great concern regarding its safety profile has been raised and the use of digoxin has declined significantly over the past two decades [15]. Indeed, in the ESC guidelines (2016), digoxin indication was limited only to patients with AF and rapid ventricular rate [16]. This could be understandable given the scarcity of randomized trials specifically aimed at testing digoxin safety in heart failure patients. The Digitalis Investigation Group (DIG) trial, the only large randomized trial of digoxin in heart failure, reported a significant reduction in heart failure hospitalizations [17]. Most of the identified studies against the use of digoxin had many potential sources of bias requiring careful assessment. In fact, digoxin safety concern comes from very heterogeneous studies and non-experimental observational studies carrying a high risk of misinterpretation [18-20]. A recent study concluded that prescription of digoxin is an indicator of disease severity and not the cause of worse prognosis which means that a significant prescription bias might be caused by the fact that sicker patients, having a higher mortality risk receive additional treatment with digoxin [21]. Currently, in DIG trial, there is no evidence of an increased risk with digoxin treatment. Importantly, DIG trial demonstrated that beneficial digoxin effects were mainly observed in patients with HFrEF and those with serum digoxin concentration ≤0.9ng/ml. Digoxin efficacy may be attributed in part to the neurohormonal-inhibiting properties of digoxin, especially in lower doses; it may also be related to its synergistic effects with beta-blockers as pro-arrhythmic effects of digoxin would be expected to be attenuated by β-blockers [22].

Our study has several limitations. First, as this is a retrospective analysis, we should clearly highlight that our results only describe associations and not causality. Second, our study is limited by its small sample size. Third, as in all case control studies; bias due to unmeasured confounders remains possible. We should have used the propensity-score matching to better match our two groups but we should point out that most of confounding variables influencing outcome were well balanced between the 2 groups of our study. Third, we had no data regarding post-discharge adherence to prescribed treatment nor we had informations on neither serum digoxin concentration nor the incidence of digoxin toxicity. We acknowledge that this important information would be a valuable support to our findings in demonstrating a correlation between serum digoxin levels and their clinical outcome in our patients. In addition, in our study only 30% of our patients were receiving aldosterone antagonists, and none were receiving cardiac resynchronization therapy, which may limit generalizability of our results.

CONCLUSION

Our findings provided an additional data to support the association between use of digoxin and clinical benefit in HF patients with reduced LVEF. Digoxin may potentially serve as an inexpensive tool for the reduction of short-term mortality and hospital readmissions which is an important objective especially in low-income countries in the health system.
References:

1. Bui AL, Horwich TB, Fonarow GC (2011) Epidemiology and risk profile of heart failure. Nat Rev Cardiol 8: 30-41.
2. Fang J, Mensah GA, Croft JB, Keenan NL (2008) Heart failure-related hospitalization in the US, 1979 to 2004. Am J Cardiol 52: 428-434.
3. Callender T, Woodward M, Roth G, Farzadfar F, Lemarie JC, et al. (2014) Heart failure care in low- and middle-income countries: a systematic review and meta-analysis. PLoS Med 11: e1001699.
4. Crespo-Leiro MG, Anker SD, Maggioni AP, Coats AJ, Filippatos G, et al. (2016) Heart Failure Association (HFA) of the European Society of Cardiology (ESC). European society of cardiology heart failure long-term registry (ESC-HF-LT): 1-year follow-up outcomes and differences across regions. Eur J Heart Fail 18: 613-625.
5. Gheorghiade M, Zannad F, Sopko G, Klein L, Piña IL, et al. (2005) International Working Group on Acute Heart Failure Syndromes. Acute heart failure syndromes: current state and framework for future research. Circulation 112: 3958-3968.
6. Yancy CW, Lopatin M, Stevenson LW, De Marco T (2006) Fonarow GC Clinical presentation, management, and in-hospital outcomes of patients admitted with acute decompensated heart failure with preserved systolic function: a report from the Acute Decompensated Heart Failure National Registry (ADHERE) database. J Am Coll Cardiol 47: 76-84.
7. Metra M, Teerlink JR, Cotter G, Davison BA, Felker GM, et al. (2019) Effects of serelaxin in patients with acute heart failure. N Engl J Med 381: 716-726.
8. Sackner Bernstein JD, Skopicki HA, Aaronson KD (2005) Risk of worsening renal function with nesiritide in patients with acutely decompensated heart failure. Circulation 111(12): 1487-1491.
9. Mebazaa A, Nieminen MS, Packer M, Cohen Solal A, Kleber FX, et al. (2007) Levosimendan vs dobutamine for patients with acute decompensated heart failure: the SURVIVE randomized trial. JAMA 297: 1883-1891.
10. Teerlink JR, Cotter G, Davison BA, Felker GM, Filippatos G, et al. (2013) Serelaxin, recombinant human relaxin-2, for treatment of acute heart failure (RELAX-AHF): a randomised, placebo-controlled trial. Lancet 381: 29-39.
11. Gheorghiade M, Konstam MA, Burnett JC, Grinfeld L, Maggioni AP, et al. (2007) Efficacy of vasopressin antagonism in heart failure outcome study with tolvaptan (EVEREST) investigators. Short-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure: the EVEREST clinical status trials. JAMA 297: 1332-1343.
12. Gheorghiade M, Braunwald E (2009) Reconsidering the role for digoxin in the management of acute heart failure syndromes. JAMA 302: 2146-2147.
13. Vamos M, Erath JW, Hohnloser SH (2015) Digoxin-associated mortality: a systematic review and meta-analysis of the literature. Eur Heart J 36: 1831-1838.
14. Packer M (2018) Why is the use of digitalis withering? Another reason that we need medical heart failure specialists. Eur J Heart Fail 20: 851-852.
15. Ambrosy AP, Butler J, Ahmed M, Vaduganathan M, van Veldhuisen DJ, et al. (2014) The use of digoxin in patients with worsening chronic heart failure: reconsidering an old drug to reduce hospital admissions. J Am Coll Cardiol 63: 1823-1832.
16. Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JG, et al. (2016) ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail 18: 891-975.
17. Digitalis Investigation Group (1997) The effect of digoxin on mortality and morbidity in patients with heart failure. N Engl J Med 336: 525-533.
18. Bavendiek U, Aguirre Davila L, Koch A, Bauersachs J (2017) Assumption versus evidence: the case of digoxin in atrial fibrillation and heart failure. Eur Heart J 38: 2095-2099.
19. Ziff OJ, Lane DA, Samra M, Griffith M, Kirchhof P, et al. (2015) Safety and efficacy of digoxin: systematic review and meta-analysis of observational and controlled trial data. BMJ 351: h4451.
20. Khan SS, Gheorghiade M (2015) Digoxin use in atrial fibrillation: a critical reappraisal. Lancet 385: 2330-2332.
21. Aguirre Dávila L, Weber K, Bavendiek U, Bauersachs J, Wittes J, et al. (2019) Digoxin-mortality: randomized vs observational comparison in the DIG trial. Eur Heart J 40: 3336-3341.
22. Katz A, Maor E, Leor J, Klempfner R (2016) Addition of beta-blockers to digoxin is associated with improved 1- and 10-year survival of patients hospitalized due to decompensated heart failure. Int J Cardiol 221: 198-204.